Think of obesity like a house with a shaky foundation built long before the walls go up. This work looks at the 'foundation' years—from before birth through the teenage years—to find the exact triggers that lead to weight gain. By using AI and biological markers, it aims to create a personalized manual for preventing obesity before it even starts.
Adult obesity treatments often fail because they ignore the biological and psychological triggers that happen before birth and during childhood. There is a lack of personalized, gender-specific tools to stop obesity before it becomes a lifelong metabolic disease.
The project is developing a system of multi-omics biomarkers and AI-driven analysis tools to identify obesity risk from the prenatal period to puberty.
If you are a medical testing laboratory dealing with a lack of early screening tools for metabolic risk—this project developed multi-omics biomarkers that allow for the identification of obesity risk during prenatal and pubertal windows.
If you are an app developer dealing with generic diet plans that fail users—this project developed AI-assisted analysis of feeding behaviors and gender-based determinants that enable tailored lifestyle interventions.
If you are a drug discovery firm dealing with low efficacy in adult obesity treatments—this project developed mechanistic analyses of blood-brain barrier permeability and epigenetic markers to identify new therapeutic targets.
Based on available project data, specific pricing or cost structures for the interventions and biomarkers have not been disclosed.
The project involves 4 industry partners and uses AI and bioinformatic technologies, which suggests a path toward scalable digital health tools, though specific industrial scaling plans are not detailed.
Based on available project data, the current status of patents or licensing agreements for the identified biomarkers is not provided.
The project is patient-centered and involves clinical studies across different maturational windows, suggesting integration into prenatal and pediatric care pathways.
The project period runs from 2023-05-01 to 2028-04-30, indicating that final results and potential commercial tools will emerge toward 2028.
The consortium is heavily research-oriented with 9 research organizations and 6 universities, but it maintains a significant commercial bridge with 4 industry partners (18% industry ratio). With 22 partners across 9 countries, the project has a strong European footprint, combining deep academic expertise in psychiatry and obesity with the practical implementation capacity of SMEs and larger firms.
Contact the Consorcio Centro de Investigacion Biomedica en Red M.P. in Spain
Contact us to track the development of these obesity biomarkers for your product pipeline.
